Warfarin Use Is Associated with Increased Mortality at One Year in Patients with Idiopathic Pulmonary Fibrosis

Table 2

Outcomes in the warfarin and DOAC groups.

Variable	Warfarin group ()	DOAC group ()	Univariable value
All-cause mortality at 1 year	7 (25%); Respiratory failure (in hospital mortality) (3); Hospice care with subsequent demise (2); Pneumonia (1); Pulmonary hemorrhage (1)	3 (6.6%); Respiratory failure (in hospital mortality) 2; Hospice care with subsequent demise (1)	0.027
Any disease exacerbation at one year	9 (32.1%)	7 (15.5%)	0.096
Any disease exacerbation requiring hospitalization in 1 year	9 (32.1%)	5 (11.1%)	0.026
Major bleeding episode at one-year follow-up	2 (7.1%)	1 (2.2%)	0.303
Major bleeding event at any time during follow-up	2 (7.1%)	4 (8.89%)	0.79
Anticoagulation failure	1 (3.6%)	1 (2.2%)	0.73